PRTA - NASDAQ
Prothena Corporation plc
$9.40
+2.3%Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
At a Glance
Live SnapshotProthena Corporation plc Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Declining FCF warrants attention. Investigate whether due to temporary factors or fundamental deterioration.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Prothena Corporation plc Cash Flow Statement
PRTA • NASDAQ
| Prothena Corporation plc Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||
-244.1M | -122.3M | -147M | -116.9M | 67M | -111.1M | -77.7M | -155.6M | -153.2M | -160.1M | -80.6M | -7.2M | -41M | -41.4M | -29.7M | -12.5M | |
895K | 893K | 928K | 744K | 1.1M | 1.5M | 6.8M | 3.2M | 3.1M | 2.4M | 806K | 743K | 660K | 468K | 391K | 191K | |
43.2M | -9.3M | -15.7M | -11.1M | 4.6M | -1.7M | -1.2M | -1.6M | -2.2M | -3.2M | -963K | -990K | -538K | 0.0 | 0.0 | 0.0 | |
37.6M | 46M | 40.9M | 31.3M | 24.7M | 22M | 23.6M | 27M | 26.8M | 24.9M | 10.4M | 5.6M | 3.1M | 6.1M | 3M | 1.6M | |
2.9M | 2.7M | 7.5M | 6M | 5.7M | 5.5M | 0.0 | 4.3M | 1.6M | -156K | -3.6M | -261K | -29K | -1.1M | 0.0 | 0.0 | |
(0.0) | (3.2M) | (1.6M) | (2.7M) | (580K) | (1.4M) | (1.6M) | (0.0) | (294K) | (575K) | (442K) | (1.6M) | (796K) | (0.0) | (0.0) | (0.0) | |
-4.2M | -67.9M | -20.5M | -18.8M | -10.4M | 3.5M | -4.4M | 94.5M | -7.2M | 18.9M | 11.5M | 1.4M | 5.7M | -7.2M | 6.6M | 1.6M | |
-163.6M | -150.1M | -133.9M | -108.8M | 92.6M | -80.4M | -53M | -28.3M | -131.2M | -117.3M | -62.5M | -683K | -32.1M | -42.1M | -19.7M | -9.1M | |
INVESTING ACTIVITIES | ||||||||||||||||
-138K | -298K | -2.8M | -464K | -575K | -196K | -555K | -1.8M | -3.6M | -16.6M | -1.4M | -526K | -564K | -1.3M | -595K | -2.6M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (39K) | (105K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | 0.0 | 37K | 0.0 | 0.0 | 0.0 | 8K | 39K | 105K | 0.0 | 0.0 | 27K | 29K | 0.0 | 0.0 | 0.0 | |
-138K | -298K | -2.8M | -464K | -575K | -196K | -547K | -1.7M | -3.5M | -16.6M | -1.4M | -499K | -535K | -1.3M | -595K | -2.6M | |
FINANCING ACTIVITIES | ||||||||||||||||
-139K | -353K | 23.6M | 223.6M | 174.8M | 0.0 | 0.0 | 39.8M | 150.3M | 128.8M | 131.3M | 117.3M | 84.5M | 26M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -4.4M | -2.8M | -169K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
(0.0) | -353K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | 1.9M | 21.5M | 17.8M | 15.5M | 215K | 228K | 4.7M | 17.8M | 25.7M | 9.5M | 736K | -84K | 142.2M | 20.3M | 11.7M | |
-139K | 1.6M | 45.1M | 241.5M | 190.3M | 215K | 228K | 40M | 165.4M | 154.3M | 140.8M | 118.1M | 84.5M | 168.2M | 20.3M | 11.7M | |
CASH FLOW SUMMARY | ||||||||||||||||
-163.9M | -148.8M | -91.6M | 132.2M | 282.4M | -80.3M | -53.3M | 10M | 30.7M | 20.4M | 77M | 116.9M | 51.8M | 124.9M | 0.0 | 0.0 | |
472.2M | 621M | 712.6M | 580.4M | 298.1M | 378.4M | 431.7M | 421.7M | 391M | 370.6M | 293.6M | 176.7M | 124.9M | 0.0 | 0.0 | 0.0 | |
308.4M | 472.2M | 621M | 712.6M | 580.4M | 298.1M | 378.4M | 431.7M | 421.7M | 391M | 370.6M | 293.6M | 176.7M | 124.9M | 0.0 | 0.0 | |
-163.7M | -150.3M | -136.7M | -109.3M | 92M | -80.6M | -53.5M | -30M | -134.8M | -133.9M | -63.8M | -1.2M | -32.7M | -43.4M | -20.3M | -11.7M |
SEC Filings
PRTA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 15, 2026 | May 14, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | March 27, 2026 | May 14, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 27, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 27, 2026 | February 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 19, 2026 | February 19, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 12, 2025 | December 10, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 19, 2025 | November 19, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 |
Related Guides
Continue your PRTA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.